Last update 10 May 2025

Pegylated recombinant canine human uricase (Shandong New Time Pharmaceutical)

Overview

Basic Info

Drug Type
Enzyme
Synonyms
F012
Target
Uric acid
Action
modulators
Mechanism
Uric acid modulators(Uric acid modulators)
Therapeutic Areas
Immune System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]
Active Indication
Hyperuricemia
Inactive Indication-
Originator Organization
Shandong New Time Pharmaceutical Co. Ltd.Shandong New Time Pharmaceutical Co. Ltd.
Active Organization
Shandong New Time Pharmaceutical Co. Ltd.Shandong New Time Pharmaceutical Co. Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Pegylated recombinant canine human uricase (Shandong New Time Pharmaceutical)
CTR20242168
/ RecruitingPhase 1
评估F012在高尿酸血症伴或不伴痛风患者中的安全性、耐受性的随机、双盲、安慰剂对照、单次给药剂量递增的I期临床研究
[Translation] A randomized, double-blind, placebo-controlled, single-dose escalation phase I clinical study to evaluate the safety and tolerability of F012 in patients with hyperuricemia with or without gout
100 Clinical Results associated with Pegylated recombinant canine human uricase (Shandong New Time Pharmaceutical)
Login to view more data
100 Translational Medicine associated with Pegylated recombinant canine human uricase (Shandong New Time Pharmaceutical)
Login to view more data
100 Patents (Medical) associated with Pegylated recombinant canine human uricase (Shandong New Time Pharmaceutical)
Login to view more data
100 Deals associated with Pegylated recombinant canine human uricase (Shandong New Time Pharmaceutical)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HyperuricemiaPhase 1
China
Shandong New Time Pharmaceutical Co. Ltd.Shandong New Time Pharmaceutical Co. Ltd.
14 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free